Oliver Luxxe Assets LLC Has $1.46 Million Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Oliver Luxxe Assets LLC cut its Amneal Pharmaceuticals stake by 46.1% in the second quarter, selling 72,068 shares and retaining 84,217 shares valued at approximately $1.46 million.
• Despite the reduction, several institutional investors increased their positions, and institutional ownership stood at 31.82% of Amneal’s outstanding stock.
• Analyst sentiment remains positive: seven analysts rate AMRX a Buy and one rates it Hold, producing a “Moderate Buy” consensus and an average price target of $17.67.

Oliver Luxxe Assets LLC decreased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 46.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 84,217 shares of the company's stock after selling 72,068 shares during the quarter. Oliver Luxxe Assets LLC's holdings in Amneal Pharmaceuticals were worth $1,458,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Bank of America Corp DE lifted its position in shares of Amneal Pharmaceuticals by 50.0% during the 1st quarter. Bank of America Corp DE now owns 676,795 shares of the company's stock valued at $8,413,000 after acquiring an additional 225,637 shares during the period. Arkadios Wealth Advisors acquired a new stake in Amneal Pharmaceuticals in the first quarter worth $4,165,000. California State Teachers Retirement System increased its stake in Amneal Pharmaceuticals by 37.6% in the first quarter. California State Teachers Retirement System now owns 207,239 shares of the company's stock valued at $2,576,000 after purchasing an additional 56,588 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Amneal Pharmaceuticals by 33.7% during the first quarter. Royal Bank of Canada now owns 12,646 shares of the company's stock valued at $157,000 after purchasing an additional 3,191 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Amneal Pharmaceuticals by 10.5% during the first quarter. The Manufacturers Life Insurance Company now owns 88,007 shares of the company's stock valued at $1,094,000 after purchasing an additional 8,347 shares during the period. Institutional investors own 31.82% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on AMRX shares. The Goldman Sachs Group restated a "buy" rating and issued a $21.00 target price on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Barclays increased their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a report on Wednesday, May 20th. UBS Group raised their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Weiss Ratings upgraded Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, July 29th. Finally, Wall Street Zen raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $17.67.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $18.14 on Monday. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. Amneal Pharmaceuticals, Inc. has a one year low of $8.21 and a one year high of $19.26. The company has a market cap of $5.79 billion, a PE ratio of 37.02 and a beta of 1.27. The firm has a 50-day moving average of $16.79 and a 200-day moving average of $14.45.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The business had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. As a group, equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source